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SIGNIFICANCE
Psoriasis is a chronic, systemic disease which is marked by 
a significant psychosocial burden. In recent years, multiple 
lines of evidence support the strong association between 
psoriasis and psychosocial comorbidities. The role of neuro­
inflammation in psoriasis pathology, sleep disruption and the 
impact of depression on cardiovascular outcomes was explo­
red in a workshop convened by the International Psoriasis 
Council. The workshop was assembled to increase the under­
standing of depression as an important comorbidity of pso­
riasis and elevate awareness of the impact of chronic, sys­
temic inflammation on neuro­ and cardiovascular outcomes. 
Studies discussed at this workshop suggest that depression 
is consistently associated with psoriasis, while suicidal idea­
tion is not. Increased awareness of and concern about effec­
tive depression management in patients with psoriasis will 
undoubtedly improve overall disease management.
Psoriasis is a systemic, relapsing, inflammatory di-
sease associated with serious comorbidities including 
mood problems and/or unhealthy lifestyle behaviours. 
Cutaneous and systemic abnormalities in innate and 
acquired immunity play a role in its pathogenesis. The 
exact pathogenetic mechanism remains elusive. Evi-
dence is accumulating that TNF-alpha, IL-17 and IL-
23 signalling are highly relevant as targeting these 
pathways reduces disease activity. Evidence suggests 
a strong link between psoriasis and depression in 
adults. The International Psoriasis Council (IPC) held 
a roundtable event, “Psoriasis and Mental Health”, in 
Barcelona, Spain which focused on the presence of de-
pression and suicidality, plus the role of neuroinflam-
mation in psoriasis, sleep disruption and the impact 
of depression on cardiovascular disease outcomes. We 
summarize here the expert presentations to provide 
additional insight into the understanding of psychiatric 
comorbidities of psoriasis and of the impact of chro-
nic, systemic inflammation on neuro- and cardiovascu-
lar outcomes. the associations between psoriasis and 
other psychiatric comorbidities are still controversial 
and warrant further attention.
Key words: psoriasis; depression; cardiovascular mental health; 
sleep; neuroinflammation.
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Psoriasis is a chronic inflammatory skin disorder with a broad and variable range of phenotypes, treatments, 
and associated comorbidities including metabolic syn-
drome (1), liver disease (2), respiratory disease (3), 
psoriatic arthritis (4), cardiovascular disease (5) and 
psychosocial disorders (6). It has been proposed that in 
psoriasis its cutaneous and specific systemic manifes-
tations are driven by a shared pathogenic inflammatory 
mechanism.
Psoriasis provides an ideal model within which to 
study relationships between chronic inflammation and 
depression and other psychiatric co-morbidities. For 
clinical practice, greater awareness of the association 
between psoriasis and depression is important (6).
The term ‘depression’ covers a range of experiences, 
from low mood symptoms that may be a transient reac-
tion to adverse life events to the enduring and potentially 
life threatening disorder. The latter is more accurately 
called Depressive Disorder (International Classification 
of Diseases [ICD-10]) or Major Depressive Disorder 
(MDD; Diagnostic and Statistical Manual of Mental 
Disorders [DSM-5]) (7, 8). Although these disorders 
are not identical constructs, they overlap to a consider-
able extent and represent a common clinical syndrome 
characterized by sustained depressed mood and/or 
anhedonia (reduced motivation for or pleasure from 
previously enjoyable activities) and impairing somatic 
(sleep, energy, sensorimotor, appetites) and cognitive 
(self-esteem, concentration) functioning as well as the 
will to live (suicidal thinking and actions). 
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DEPRESSION AND NEUROINFLAMMATION
An influential current hypothesis of the neurobio-
logy of MDD emphasizes a complex and interacting 
dysregulation of endocrine, immune, and monoami-
ne neurotransmitter systems, often triggered initially 
by environmental stress but gradually becoming 
self-sustaining and resulting in impaired regional 
brain structure and function (9, 10).
Thus, chronic stress activates the hypothalamic-pi-
tuitary-adrenal (HPA) axis resulting in increased rele-
ase of glucocorticoids from the adrenal cortex which, 
in turn, dysregulates amygdala function (Fig. 1) 
(10). The elevated adrenal activity and associated 
increase in sympathetic tone causes the release of 
proinflammatory cytokines which, along with the 
increased glucocorticoids, increase the activity of 
the enzyme monoamine oxidase (MAO) which in 
turn causes reduced levels of the monoamine neu-
rotransmitters serotonin (5-HT), noradrenaline, and 
dopamine. The elevated cytokines and glucocorticoids 
also depress neurotrophic factors such as brain-derived 
neurotrophic factor (BDNF) resulting in decreased neuro-
genesis in the hippocampus and reduced hippocampal 
volume. Amygdala and hippocampus dysregulation then 
maintains abnormal glucocorticoids, BDNF and cytoki-
nes, and increased proinflammatory cytokines give rise to 
physical illness symptoms and increased risk of inflam-
matory disorders such as cardiovascular disease (CVD). 
Stress has been shown to trigger psoriasis onset and 
contribute to psoriasis flares in patients (6). The role of 
the HPA axis activity dysregulation and the link to the 
modulation of immune response in psoriasis have been 
explored (11, 12).  Verhoeven et al. (13) demonstrated 
that flares of psoriasis are characterised by high activity 
of daily stressors and low cortisol levels. Furthermore, 
patients with persistently high levels of stressors have 
related lowered cortisol levels and may be particularly 
vulnerable to the influence of stressors on their psoriasis. 
NEUROIMAGING 
A number of changes in the HPA axis have been identified 
by neuroimaging. Molecular positron emission tomo-
graphy (PET) studies during major depressive episodes 
(MDE), have found significantly elevated density of 
MAO-A  – which could result in chronically low synaptic 
5-HT levels through increased metabolism in a range of 
brain regions. Further evidence from PET studies demon-
strates that 5-HT1A receptors (14) and 5-HT2A receptors 
(15, 16) are upregulated in MDD, suggesting an adaptive 
response to reduced 5-HT transmission, and that higher 
levels of 5-HT1A receptors predict higher suicidal ideation 
and attempts of greater lethality and intent (17).
Functional magnetic resonance imaging (fMRI) shows 
the amygdala is overly active in people with MDD when 
shown sad stimuli, but under-active when shown positive 
stimuli (18), suggesting a neural basis for the negative 
cognitive bias in MDD which is the therapeutic target 
of cognitive behavioural therapy.
Increasing evidence suggests involvement of inflam-
mation in MDD in a proportion of individuals (19–22). 
Inflammatory disorders such as psoriasis are associated 
with a high prevalence of depression (23, 24). Similarly, 
symptoms of depression develop in a high proportion of 
patients administered pro-inflammatory cytokines for 
therapeutic reasons (25–27) and in healthy volunteers fol-
lowing peripheral immune challenges, such as vaccination 
or bacterial endotoxin injection, which result in a mild 
immune activation (28, 29). In MDD, several peripheral 
pro-inflammatory cytokines are elevated (30–33) and 
polymorphisms in inflammatory cytokine genes are as-
sociated with MDD and treatment response (34). Several 
PET studies have now investigated whether MDD is also 
associated with evidence for central neuroinflammation 
using tracers specific for the 18 kDA translocator protein 
(TSPO), a mitochondrial membrane protein which is over-
expressed on activated microglia and, to a lesser extent, 
astrocytes. One study did not find elevated TSPO during 
a mild-to-moderate MDE (35). However, a subsequent 
study in more severely symptomatic patients (moderate-
to-severe MDE) found significantly elevated TSPO, 
most prominent in prefrontal cortex, anterior cingulate 
cortex (ACC), and insula, and positively correlated with 
symptom severity (36). More recent data from a clinically 
and demographically comparable cohort of patients in a 
moderate-to-severe MDE replicates the TSPO elevation 
in the ACC, but suggests that microglial activation may be 
more strong ly associated with the presence of suicidality 
than the diagnosis of MDD itself (37). These studies in 
working age adults with MDD are supported by the finding 
of elevated ACC TSPO in a recent small PET study in pa-
tients with late-life depression who had largely recovered 
from a depression episode but who had remaining evidence 
of peripheral inflammation (38). Thus, PET evidence for 
Fig. 1. Hypothalamic-pituitary-adrenal (HPA) axis and depression. BDNF: 
brain­derived neurotrophic factor; CRH: corticotropin­releasing hormone; DA: 
dopamine; 5HT: serotonin; NE: noradrenaline.
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neuroinflammation in MDD, and potentially suicidality, 
seems to be converging on the ACC, a brain region playing 
an important role in regulating cognitive and emotional 
processing (39). Interestingly, no PET evidence for neuro-
inflammation was found in non-depressed patients with 
moderate-to-severe plaque psoriasis and raised peripheral 
cytokines (40). However, a comparable study in depres-
sed psoriasis patients has not yet been conducted, and the 
neurobiological mechanism underlying the increased inci-
dence of depression in psoriasis remains to be elucidated. 
More recently increased TSPO binding has been 
shown in the brains of patients with MDD and post hoc 
analysis extended these findings by demonstrating that 
this abnormality is significant in unmedicated but not in 
medicated MDD subjects (41). Moreover, in drug-naïve 
patients in a moderate-severe MDE, improvement in de-
pressive symptoms following successful psychotherapy 
has been shown to be associated with a normalisation of 
elevated TSPO (42). 
DEPRESSION AND PSORIASIS
Depending on the screening method used, depression 
prevalence estimates vary between 9 and 55% of people 
with psoriasis (43, 44). One meta-analysis and systema-
tic review estimated rates of clinical depression at 28% 
using questionnaires while estimates were 12% using 
International Classification of Diseases codes, 19% using 
Diagnostic and Statistical Manual of Mental Disorders 
IV, and 9% for antidepressant use (24). Psoriasis patients 
in this study had significantly more depressive symptoms 
(standardized mean differences 1.16; 95% confidence 
interval (CI) 0.67–1.66), and population-based studies 
showed that they were at least one and a half times more 
likely to experience depression (odds ratio [OR] 1.57; 
95% CI 1.40–1.76) and used more antidepressant medi-
cation than did controls (OR 4.24, 95% CI 1.53–11.76) 
(Table I). In a multicentre study (45), 13.8% of patients 
with psoriasis reported depression symptoms using the 
Hospital Anxiety and Depression scale (HADS) versus 
4.3% in controls (OR 2.40, 95% CI 1.67–3.47)).
Furthermore, in a study including 607 patients with 
psoriasis, 9.9% (95% CI: 7.5–12.3%) screened positive 
for MDD, measured using the (Patient Health Question-
naire -9 items) PHQ-9 (46). Of these, 42% reported 
severe symptoms and 25% met criteria for urgent mental 
health specialist referral. Interestingly, in the 71% of 
patients from the cohort that identified with severe de-
pression, this clinical finding was de novo. In the patient 
group diagnosed with MDD, 39% had a Dermatology 
Life Quality Index (DLQI) score <10 indicating low to 
medium impact of psoriasis on quality of life. Therefore, 
using the DLQI alone would potentially miss important 
depression symptoms that were detected by the PHQ-9.
Severity of psoriasis, as determined by a code for syste-
mic medications, was found to be associated with higher Ta
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risk of receiving a clinical diagnosis of depression, 
as evidenced by a hazard ratio of 1.72 (CI 1.57–1.88) 
in severe psoriasis compared to a hazard ratio of 1.38 
(CI 1.35–1.40) in mild psoriasis (47). Depression may 
act as a trigger or exacerbating factor for psoriasis and 
may also be a consequence of the disease. Jensen et 
al. (48) examined the risk of new-onset depression in 
patients with psoriasis in a nationwide Danish cohort 
of 5 million people in the timeframe 2001–2011. In a 
total of 35,001 patients with mild psoriasis and 7,510 
with severe psoriasis, incidence rates for depression 
were 20.0% (95% CI:19.9–20.0), 23.9% (23.1–24.7) 
and 31.6% (29.5–33.8) for the reference population, 
mild, and severe psoriasis, respectively. This finding 
indicates that in patients with severe disease new onset 
depression is more frequent.
In a Brazilian study, PASI (Psoriasis Area Severity 
Index), DLQI, State-Trait Anxiety Inventory (STAI) 
questionnaire, PHQ-9 and Holmes and Rahe Life Events 
scale were used to assess the total “load” of stressful 
life events in 119 psoriasis patients having experienced 
psoriasis for 3 years or more years and moderate severity 
(49). Salivary cortisol was assessed. The DLQI and stress 
questionnaire results demonstrated 20% of patients with 
depression, and nearly 20% of patients reported severe 
or very severe impact on QoL. The biometric study sho-
wed a positive correlation (r = 0.39, p < 0.001) between 
salivary cortisol values at bedtime and the PASI score. 
The association of psoriasis with anxiety and psycho-
logical stress is well established.  In order to evaluate 
psycho logical impact, it is important to use instruments 
such as the HADS and PHQ-9, which are validated 
measures of anxiety and depressive symptomatology. 
Studies have demonstrated that using the DLQI to mea-
sure impact on life is not sufficient to identify depression 
as about one in 3 patients with MDD or major anxiety 
reported low to medium DLQI scores (46). 
Effective biologic psoriasis treatments reduce signs 
and symptoms of psoriasis, lower disease impact (DLQI) 
and may also improve mental health outcomes (50, 51). 
Examination of depression through a prospective, longi-
tudinal psoriasis registry (PSOLAR) demonstrated that 
treatment with biologics in moderate-to-severe psoriasis 
patients may reduce the risk of depressive symptoms 
(50). Similarly, a large cross-sectional study consisting 
of over 2 million patients with moderate-to-severe pso-
riasis demonstrated reduction of psychological stress and 
depression, in patients treated with biologics compared 
to those treated with oral therapies as measured by the 
Kessler Psychological Distress Scale- 6 (K6) and Patient 
Health Questionnaire-2 (PHQ2) tools (51). 
DEPRESSION AND SUICIDALITY IN PSORIASIS
The association between psoriasis, depression and suici-
dal ideation has been summarized in Table I. Depression 
and suicidal ideation tend to be more frequent in patients 
with severe disease. Although depression is consistently 
associated with psoriasis, suicidal ideation is not (52, 53). 
One cross-sectional multicentre study found that suicidal 
ideation was significantly associated with psoriasis (45) 
and some studies indicate that psoriasis is significantly 
linked to all 3 measures of suicidality (54), but the avail-
able data on suicide attempts and death by suicide is 
limited and less consistent. Younger patients and patients 
with more severe psoriasis are at significantly higher 
risk of suicidality (54). Higher levels of psoriasis-related 
stressors and reduced QoL were significantly associated 
with suicidality in people with psoriasis.
A large population-based study utilizing a primary care 
database in the United Kingdom with linked hospital 
and mortality records indicated that the prevalence of 
depression was raised in patients with psoriasis and this 
may lead to a greater risk of self-harm. Nevertheless, the 
risk of suicide was lower in patients with psoriasis com-
pared with those without psoriasis, and it was postulated 
that increased contacts with healthcare professionals for 
treatment of skin and coexistent depression may have 
ameliorated suicide risk (55).
DEPRESSION AND ALEXITHYMIA IN PSORIASIS
Alexithymia, the difficulty in recognising and describing 
emotions as measured by the Toronto Alexithymia Scale 
(TAS-20), has been linked to psoriasis. The observed 
prevalence of alexithymia in patients with psoriasis 
ranges between approximately 15.6% and 33%, which 
is significantly higher than found among the general 
public (56–59). In a multicentre study which included 
670 patients with psoriasis, the prevalence of alexithymia 
was 24.8% (95% CI: 21.7–28.2) (59). Some studies have 
shown that alexithymia is stable over time in the general 
population (60). However, it may be partly modifiable 
with therapeutic interventions, and reversal of alexithy-
mia improves QoL, anxiety and depression (61, 62). It 
is likely that “trait alexithymia” and “state alexithymia” 
exist  – the latter may be modified by therapeutic inter-
vention or change in psychological status. It is important 
to identify alexithymic patients with psoriasis in clinical 
practice as they suffer from a higher disease burden, 
including significant impairment of QoL, higher levels 
of anxiety and depression, higher risk of alcohol depen-
dency and impairment of work productivity, compared 
to patients without alexithymia (63). 
SLEEP DISRUPTION, DEPRESSION AND 
PSORIASIS 
Sleep is a complex behavioural and physiological pro-
cess necessary for healthy functioning of the immune 
and metabolic systems, neuro-cognitive activity and 
emotional regulation. There is a large body of evidence 
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demonstrating the vital role sleep has in maintaining 
health (64–66) and optimal physiological (67) and 
psychological functioning (68, 69). Persistent sleep 
disturbance is related to a number of medical illnesses 
including diabetes (70) and has established relationships 
with depression (71, 72).
Sleep disturbance is associated with a range of adverse 
health outcomes including elevated risk for a range of 
physical diseases, several of which people with psoriasis 
are already more susceptible to (e.g. diabetes (73), hyper-
tension (74), CVD (75). Moreover, sleep disturbance in-
creases risk of psychological illness (e.g. depression (72), 
anxiety (76)) and, over time, all-cause mortality (77).
Sleep disruption, including obstructive sleep apnoea 
(OSA), may contribute significantly to the health outco-
mes of psoriasis. A recent study (78) (186 respondents; 
mean age 39.2 years) assessed validated measures of 
sleep [Pittsburgh Sleep; Quality Index (PSQI), Berlin 
Questionnaire, Pre-Sleep Arousal Scale]; chronotype 
(Morningness-Eveningness Questionnaire); mood (Hos-
pital Anxiety and Depression Scale); itch (5-D Itch Sca-
le); and psoriasis severity (Simplified Psoriasis Index). 
The mean PSQI score was 9.2 ± 4.3, with 76.3% scoring 
above the threshold for poor sleep (≥ 6 on the PSQI) and 
32.5% scoring ‘positive’ for probable OSA. Poor sleep 
and high likelihood of OSA were associated with more 
severe psoriasis (p < 0.05; η = 0.07; η2 = 0.005) (78). The 
precise mechanisms explaining the health outcomes and 
sleep link are not fully understood but are thought to 
include disrupted cortisol and cytokine production and 
changes in body temperature control all of which are 
implicated in psoriasis.
PSORIASIS, DEPRESSION AND 
CARDIOVASCULAR EVENTS
Not only is psoriasis accompanied by an increased risk of 
psychiatric comorbidities, but in particular when coupled 
with these comorbidities, such as depression, psoriasis 
promotes a greater risk of CVD events (79). 
Due to the complex interaction of psoriasis and co-
morbidities, evidence is accumulating that psoriasis 
may trigger the metabolic syndrome and cardiovascular 
comorbidities. This relationship may be multifactorial, 
comprising lifestyles and systematic inflammation. Re-
cently it was shown that blockade of IL12/23 reduced 
aortic vascular inflammation (80). 
On the other hand these comorbidities may aggravate 
psoriasis. Recently, a Mendelian randomization study 
showed a causal relationship between body mass index 
(BMI) and psoriasis, whereas there was little support to 
a possible causal effect of psoriasis genetic risk (81).
The link between psoriasis, depression and CVD 
was investigated in a nationwide Danish cohort of pa-
tients with psoriasis (n = 29,406). Incidence rates were 
calculated, and incidence rate ratios (IRRs) adjusted 
for age, gender, socio-economic status, medication 
and comorbidity were estimated by Poisson regression 
models. Risk of myocardial infarction (MI) (IRR 1.57, 
95% confidence interval (95% CI) 1.07–2.29), stroke 
(IRR 1.95, 95% CI 1.43–2.66), and death from CVD 
(IRR 2.24, 95% CI 1.53–3.26) were increased signifi-
cantly during acute depression, and risk of stroke (IRR 
1.51, 95% CI 1.19–1.90) was increased significantly in 
chronic depression. During remission from depression, 
only the risk of stroke was increased. In patients with 
psoriasis, depression is associated with increased risk 
of MI, stroke and death from CVD, especially during 
acute depression (82). These findings suggest that the 
added burden of comorbid depression in patients with 
psoriasis confers a greater risk of major adverse CVD 
events.    
To further understand whether the impact of psoriasis 
and comorbid depression occurred prior to CVD events, 
36 patients with psoriasis and reported comorbid depres-
sion and 36 age- and sex-matched patients with psoriasis 
but no reported history of psychiatric illness were en-
rolled in a study for quantifying vascular inflammation 
and coronary CT angiography using 18-FDG PET/CT 
(83). Patients with psoriasis and comorbid depression 
experienced both greater vascular inflammation and 
greater total and non-calcified coronary plaque burden 
when compared to psoriasis patients without comorbid 
psychiatric illness. These differences remained signifi-
cant after adjustment for age, sex and Framingham risk 
score, suggesting that comorbid depression in psoriasis 
contributes to CVD risk beyond what can be attributed 
to traditional cardiovascular risk factors.
Additionally, a prospective cohort study demonstrated 
that chronic psychological stress increases neural acti-
vity, as measured by amygdala activity, in patients with 
severe psoriasis disease compared to healthy volunteers 
(84). Elevated neural activity was found to significantly 
contribute to the risk of subclinical CVD in patients 
with psoriasis. Skin clearance after one year of treatment 
corresponded with reduction of amygdala activity and 
subclinical CVD factors. Taken together, these studies 
highlight the strong link between psychological stress 
and CVD morbidity in psoriasis.
 Unfortunately, so far no predictive models nor bio-
markers are available to predict the course of the disease 
and in particular the development of comorbidities. 
Several studies however suggest that predictive models 
may become available in the near future. For example, 
a genome-wide analysis of the British Association of 
Dermatologists Biologics and Immunomodulators Re-
gister (BADBIR) revealed that HLA-C*06:02-negative 
patients responded better to adalimumab, whereas HLA-
C*06:02-positive patients responded better to treatment 
with ustekinumab (85). Another analysis of this registry 
indicated that various baseline clinical characteristics 
predict response to treatment with biologics (86). 
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CONCLUSIONS 
Psoriasis, depression and CVD are associated and are 
probably connected through systemic inflammation; 
neuroimaging has provided evidence for the common 
inflammatory pathway connecting these conditions. 
The interaction of psychological stress with the inflam-
matory state of psoriasis and depression is complex and 
poorly understood. Stressful life events can trigger onset, 
exacerbate and initiate flares of psoriasis. In addition, 
social interactions, economic challenges, and negative 
behaviours (alcohol and smoking) also contribute to the 
complex interactions of these conditions. 
The association between psoriasis and distress is 
broader than depression alone. Psychological stress 
and anxiety are also well established features in many 
patients with psoriasis and are aggravating or precipi-
tating factors of depression. Alexithymia, which is also 
linked to depression, warrants further investigation. Of 
note, the association between psoriasis and death by 
suicide may be a matter of debate but suicidal ideation 
is more frequently associated with psoriasis. 
The impairment of patient QoL by psoriasis is common 
knowledge and is of major importance in the assessment 
of treatment outcomes. However, awareness of the asso-
ciation of psoriasis with depression, although established 
in epidemiological studies, is less well-recognised and 
addressed in the clinic. Early diagnosis of depression 
through validated tools and insight into related psycholo-
gical/psychiatric disorders should form important targets 
in the treatment of patients with psoriasis.
Increased awareness of and concern about effective 
depression management in patients with psoriasis will 
undoubtedly improve overall disease management. Quick 
and easy to perform screening tools for depression and 
suicidal ideation are necessary if we hope to add depres-
sion screening to our clinical repertoire for managing 
psoriasis patients. For example, The PHQ-2 is a validated 
measure that screens for depressed mood and anhedonia 
over the past 2 weeks and includes the first two questions 
of the PHQ-9 and may prove useful for mood assess-
ment. Many dermatologists report feeling ill-equipped 
to address psychological/psychiatric comorbidity in the 
clinic so  implementation of resources to increase the 
accessibility of psychological support and psychiatric 
referral in dermatologic practices, and especially in the 
setting of psoriasis dedicated units in referral centers is 
key. Further research is needed in order to understand 
how targeting specific pro-inflammatory cytokines which 
underlie the chronic inflammation of psoriasis affects 
both CVD events and depression.
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